Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20163990 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)

Indicates status has not been verified in more than two years